Zepatier® (elbasvir/grazoprevir) – Expanded indication
On December 9, 2021, the FDA approved Merck’s Zepatier (elbasvir/grazoprevir), for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg.
Download PDF
